New Report Available: Belarus Pharmaceuticals & Healthcare Report Q2 2013
We expect the volatility in the performance of the Belarusian pharmaceutical market to continue, with political tensions increasing risks to our forecasts. Although the government aims to increase local output and meet at least half of domestic drug demand, we note that currency devaluation would have significantly increased the price of imported raw materials and manufacturing equipment. At the same time, the country's political stance may potentially disrupt supplies of high-tech medicines currently imported from a number of developed markets.
View full press release